当前位置: 首页 > 期刊 > 《医学新知杂志》 > 2012年第3期
编号:12278517
老年高血压的临床特点及药物治疗进展(4)
http://www.100md.com 2012年6月1日 《医学新知.综合版》 2012年第3期
     [19]Dahlof B, Devereux R B, Kjeldsen S E,et al.Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study(LIFE): a randomised trial against atenolol[ J].Lancet,2002, 359(9311): 995-1003.

    [20]Macmahon S, Neal B, Tzourio C,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack[J].Lancet,2001, 358(9287): 1033-1041.

    [21]Beckett N S, Peters R, Fletcher A E,et al.Treatment of hypertension in patients 80 years of age or older[J].N EnglJMed, 2008, 358(18): 1887-1898.

    [22]Mancia G, Grassi G.The international nifedipine GITS study of intervention as a goal in hypertension treatment (INSIGHT) trial [ J].Am J Cardiol,1998, 82 (9B):23R-28R.

    [23]Julius S, Kjeldsen S E, Weber M,et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomised trial[J].Lancet, 2004, 363: 200 2-2031.

    [24]LIU L S, ZHANG Y Q, LIU G Z,et al. The felodipine event reduction study: a randomized long-term placebo-controlled trial in chinese hypertensive patients[J].JHypertens,2005, 23(12): 2157-2172.

    [25]杨瑞丽,张 龙,杜传荣.老年高血压肾损害相关因素及临床分析[J].山东医药, 2008; 48(42): 54-5., http://www.100md.com(黄著统 任桂梅)
上一页1 2 3 4